Anti-cancer effects of pyrazole-platinum(II) complexes combined with anti-MUC1 monoclonal antibody versus monotherapy in DLD-1 and HT-29 colon cancer cells

Supruniuk, Katarzyna; Czarnomysy, Robert; Muszyńska, Anna; Radziejewska, Iwona

doi:10.1016/j.tranon.2022.101348

Cited by 8 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among mucin protein family, MUC1 was reported to exhibit a role in tumorigenesis by cell death inhibition and metastasis promotion [ 46 , 47 ]. One study combined monoclonal antibodies against MUC1 with chemotherapeutic agents and showed combined therapy applied in DLD-1 cells induced more apoptosis compared with monotherapy [ 48 ]. This report is partly consistent with the current IHC staining result in DLD-1 cells.…”

Section: Discussionmentioning

confidence: 99%

Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer

et al. 2023

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) is highly prevalent and lethal globally, and its prognosis remains unsatisfactory. Drug resistance is regarded as the main cause of treatment failure leading to tumor recurrence and metastasis. The overexpression of fucosylated epitopes, which are usually modifications of glycoproteins, was reported to occur in various epithelial cancers. However, the effects of treatments that target these antigens in colorectal cancer remain unclear. Methods This study investigated the expression of heavily fucosylated glycans (HFGs) in 30 clinical samples from patients with CRC and other normal human tissues. The complement-dependent cytotoxicity was explored in vitro through treatment with anti-HFG monoclonal antibody (mAb) alone or in combination with chemotherapeutic agents. In vivo inhibitory effects were also examined using a xenograft mouse model. Results Immunohistochemistry staining and western blotting revealed that HFG expression was higher in human colorectal cancer tissues than in normal tissues. In DLD-1 and SW1116 cells, which overexpress fucosylated epitopes, anti-HFG mAb produced observable cytotoxic effects, especially when it was combined with chemotherapeutic agents. The xenograft model also demonstrated that anti-HFG mAb had potent and dose-dependent inhibitory effects on colorectal tumor growth. Conclusions As a novel cancer antigen, HFGs are a promising treatment target, and the implementation of anti-HFG mAb treatment for CRC warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Based on this theory, in recent years, many studies have found the target of MUC1 anti-tumor vaccine, and the results showed that the survival rate was improved ( 101 ) and the metastatic foci were reduced in the mouse model. In the experiment of human colorectal cancer cells, anti MUC1 shows potential for colorectal cancer treatment ( 102 , 103 ). Targeting MUC1-C to inhibit the AKT-S6K1-elF4A pathway regulates TIGAR translation in colorectal cancer and inhibits the growth of colon cancer cells in vitro ( 104 ).…”

Section: C1galt1 In Colorectal Cancermentioning

confidence: 99%

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression

Tian,

Yu,

Chu

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

C1GALT1 plays a pivotal role in colorectal cancer (CRC) development and progression through its involvement in various molecular mechanisms. This enzyme is central to the O-glycosylation process, producing tumor-associated carbohydrate antigens (TACA) like Tn and sTn, which are linked to cancer metastasis and poor prognosis. The interaction between C1GALT1 and core 3 synthase is crucial for the synthesis of core 3 O-glycans, essential for gastrointestinal health and mucosal barrier integrity. Aberrations in this pathway can lead to CRC development. Furthermore, C1GALT1's function is significantly influenced by its molecular chaperone, Cosmc, which is necessary for the proper folding of T-synthase. Dysregulation in this complex interaction contributes to abnormal O-glycan regulation, facilitating cancer progression. Moreover, C1GALT1 affects downstream signaling pathways and cellular behaviors, such as the epithelial-mesenchymal transition (EMT), by modifying O-glycans on key receptors like FGFR2, enhancing cancer cell invasiveness and metastatic potential. Additionally, the enzyme's relationship with MUC1, a mucin protein with abnormal glycosylation in CRC, highlights its role in cancer cell immune evasion and metastasis. Given these insights, targeting C1GALT1 presents a promising therapeutic strategy for CRC, necessitating further research to develop targeted inhibitors or activators. Future efforts should also explore C1GALT1's potential as a biomarker for early diagnosis, prognosis, and treatment response monitoring in CRC, alongside investigating combination therapies to improve patient outcomes.

show abstract

“…Mucin genes such as muc1 and muc4 are expressed broadly in epithelial cells of the body, including the upper aero-respiratory tract and oral cavity [40]. Over-and under-expression of mucin genes and other modifications, such as aberrant glycosylation, have been implicated in situations of epithelial dysfunction, including malignant transformation [41,42] and breakdown of the nasal epithelial barrier [43]. For the OKF6/TERT-2 cell model to be representative of in vivo physiology, the production of mucins should remain consistent.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Culture Media for <em>in-vitro</em> Expansion of Oral Epithelial Keratinocytes: Implications for Testing E-liquid Flavors

Cuadra¹,

Shamim²,

Shah³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Understanding in vitro expansion of OKF6/TERT-2 oral epithelial cells is important for studying molecular biology of disease and pathology affecting the oral cavity. The media used for any cell culture is paramount in terms of efficient output. Therefore, this study aims to compare two different media for OKF6/TERT-2 cultures: Keratinocyte Serum-Free Medium (KSFM) and a composite medium comprised of DMEM/F-12 mixed with KSFM (referred to as DFK). For application purposes, this investigation also compares the toxicological effects of flavored electronic cigarette liquids (E-liquids) on OKF6/TERT-2 cultures grown in both media. Methods: Cells were grown in KSFM and DFK media and cellular growth, morphology, gene expression of mucins and tight junctions, as well as wound-healing were determined. Additionally, cellular viability and cytotoxicity were indexed after E-liquid exposures. Results: While overall cellular morphologies remained unaltered, cells grown in DFK reached confluency faster. Except for claudin-1, there is no appreciable difference in expression of the other genes tested. Additionally, cultures in DFK appear more sensitive to E-liquids ± flavors. Conclusions: DFK is an alternative medium for cultivation of OKF6/TERT-2 cells to study molecular biology of disease and pathology, such as their responses to E-liquids ± flavors.

show abstract

Anti-cancer effects of pyrazole-platinum(II) complexes combined with anti-MUC1 monoclonal antibody versus monotherapy in DLD-1 and HT-29 colon cancer cells

Cited by 8 publications

References 42 publications

Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer

Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression

Comparison of Culture Media for <em>in-vitro</em> Expansion of Oral Epithelial Keratinocytes: Implications for Testing E-liquid Flavors

Contact Info

Product

Resources

About